CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Access to training facilityWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug254 Aviptadil by intravenous infusion + standard of care Wiki 1.00
drug1644 Normal Saline Infusion + standard of care Wiki 1.00

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.21
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Rapid-Cycle Re-Implementation of TRAining Facilities in Norway

This study tests the randomized re-opening of training facilities in Norway in relation to the COVID-19 pandemic. The investigators will use the recently developed concept of rapid-cycle randomized implementation to assure fast and safe re-introduction of training facilities by randomized testing of access restriction and measure virus exposure and immunity as well as clinical disease during the intervention to enable safe and timely downgrading of COVID-19 restrictions. Members of training facilities in Norway age 18 to 64 years without COVID-19 related comorbidity will after informed consent be randomised to either access to training or no access in a first 2-week cycle. Testing for COVID-19 and ascertainment of clinical disease will be performed after the first cycle. If there is no clinically meaningful difference between the arms, new cycles may be implemented subsequently, e.g. with less distancing restrictions or wider age groups.

NCT04406909 Training Other: Access to training facility

Primary Outcomes

Description: Percentage of COVID-19 RNA positive individuals

Measure: COVID-19 RNA test positivity

Time: At the end of Cycle 1 (cycle length is 14 days)

Description: Percentage of people admitted to hospital for COVID-19

Measure: Hospital admission for COVID-19

Time: 7 days after the end of Cycle 1 (cycle length is 14 days)

Secondary Outcomes

Description: Percentage of individuals with COVID-19 antibodies by blood sampling

Measure: individuals with COVID-19 antibodies

Time: 14 to 20 days after the end of Cycle 1 (cycle length is 14 days)

Description: Percentage of people who had any contacs with primary or secondary health care services

Measure: Percentage of individuals with health care contacts

Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)

Description: Percentage of people in need of ventilator after hosital admission for COVID-19

Measure: Need of ventilator treatment after hospital admission for COVID-19

Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)

Description: Percentage of people admitted to the ICU for COVID-19

Measure: ICU admission for COVID-19

Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)

Description: Percentage of people who died, with cause of death (including underlying cause of death)

Measure: Cause-specific death

Time: 7 days and 3 months after the end of Cycle 1 (cycle length is 14 days)

Description: Percentage of COVID-19 RNA positive employees who worked at the training centres during the intervention

Measure: COVID-19 RNA test positivity in employees at training centres

Time: At the end of Cycle 1 (cycle length is 14 days)

No related HPO nodes (Using clinical trials)